bMSAF is a prognostic predictor for advanced hepatocellular carcinoma patients treated with immune checkpoint inhibitor camrelizumab and anti‐angiogenic agent apatinib combination therapy

• Gehan Xu,
• Liang Cui,
• Jin Li,
• Quanren Wang,
• Pansong Li,
• Xuefeng Xia,
• Xin Yi,
• Quanlin Guan,
• Jianming Xu

Affiliations

Gehan Xu

The First Clinical Medical College of Lanzhou University Lanzhou China

Liang Cui

Geneplus‐Beijing Institute Beijing China

Jin Li

Geneplus‐Beijing Institute Beijing China

Quanren Wang

Jiangsu Hengrui Medicine Co. Ltd. Jiangsu China

Pansong Li

Geneplus‐Beijing Institute Beijing China

Xuefeng Xia

Geneplus‐Beijing Institute Beijing China

Xin Yi

Geneplus‐Beijing Institute Beijing China

Quanlin Guan

Department of Oncology Surgery The First Hospital of Lanzhou University Lanzhou China

Jianming Xu

Department of Gastrointestinal Oncology The Fifth Medical Center Chinese PLA General Hospital Beijing China